NKGen Biotech, Inc. Warrants
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refracto… Read more
Market Cap & Net Worth: NKGen Biotech, Inc. Warrants (NKGNW)
NKGen Biotech, Inc. Warrants (NASDAQ:NKGNW) has a market capitalization of $322.92 ($322.92) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #37232 globally and #12126 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NKGen Biotech, Inc. Warrants's stock price $0.03 by its total outstanding shares 9360 (9.36K).
NKGen Biotech, Inc. Warrants Market Cap History: 2021 to 2025
NKGen Biotech, Inc. Warrants's market capitalization history from 2021 to 2025. Data shows change from $12.17K to $322.92 (-62.17% CAGR).
NKGen Biotech, Inc. Warrants Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NKGen Biotech, Inc. Warrants's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
NKGen Biotech, Inc. Warrants's market cap is 0.01 times its annual revenue
1742.66x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $12.17K | $426.00K | -$23.27 Million | 0.03x | N/A |
| 2022 | $794.66 | $77.00K | -$26.75 Million | 0.01x | N/A |
Competitor Companies of NKGNW by Market Capitalization
Companies near NKGen Biotech, Inc. Warrants in the global market cap rankings as of March 18, 2026.
Key companies related to NKGen Biotech, Inc. Warrants by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
NKGen Biotech, Inc. Warrants Historical Marketcap From 2021 to 2025
Between 2021 and today, NKGen Biotech, Inc. Warrants's market cap moved from $12.17K to $ 322.92, with a yearly change of -62.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $322.92 | -65.50% |
| 2024 | $936.00 | +23.76% |
| 2023 | $756.29 | -4.83% |
| 2022 | $794.66 | -93.47% |
| 2021 | $12.17K | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of NKGen Biotech, Inc. Warrants was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $322.92 USD |
| MoneyControl | $322.92 USD |
| MarketWatch | $322.92 USD |
| marketcap.company | $322.92 USD |
| Reuters | $322.92 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.